OBJECTIVE: To determine whether aggressive treatment initiated early in the course of rheumatoid factor (RF)-positive or RF-negative polyarticular juvenile idiopathic arthritis (JIA) can induce clinical inactive disease within 6 months. METHODS: Between May 2007 and October 2010, a multicenter, prospective, randomized, double-blind, placebo-controlled trial of 2 aggressive treatments was conducted in 85 children ages 2-16 years with polyarticular JIA of <12 months' duration. Patients received either methotrexate (MTX) 0.5 mg/kg/week (maximum 40 mg) subcutaneously, etanercept 0.8 mg/kg/week (maximum 50 mg), and prednisolone 0.5 mg/kg/day (maximum 60 mg) tapered to 0 by 17 weeks (arm 1), or MTX (same dosage as arm 1), etanercept placebo, and prednisolone placebo (arm 2). The primary outcome measure was clinical inactive disease at 6 months. An exploratory phase determined the rate of clinical remission on medication (6 months of continuous clinical inactive disease) at 12 months. RESULTS: By 6 months, clinical inactive disease had been achieved in 17 (40%) of 42 patients in arm 1 and 10 (23%) of 43 patients in arm 2 (χ(2) = 2.91, P = 0.088). After 12 months, clinical remission on medication was achieved in 9 patients in arm 1 and 3 patients in arm 2 (P = 0.053). There were no significant interarm differences in adverse events. CONCLUSION: Although this study did not meet its primary end point, early aggressive therapy in this cohort of children with recent-onset polyarticular JIA resulted in clinical inactive disease by 6 months and clinical remission on medication within 12 months of treatment in substantial proportions of patients in both arms.
RCT Entities:
OBJECTIVE: To determine whether aggressive treatment initiated early in the course of rheumatoid factor (RF)-positive or RF-negative polyarticular juvenile idiopathic arthritis (JIA) can induce clinical inactive disease within 6 months. METHODS: Between May 2007 and October 2010, a multicenter, prospective, randomized, double-blind, placebo-controlled trial of 2 aggressive treatments was conducted in 85 children ages 2-16 years with polyarticular JIA of <12 months' duration. Patients received either methotrexate (MTX) 0.5 mg/kg/week (maximum 40 mg) subcutaneously, etanercept 0.8 mg/kg/week (maximum 50 mg), and prednisolone 0.5 mg/kg/day (maximum 60 mg) tapered to 0 by 17 weeks (arm 1), or MTX (same dosage as arm 1), etanercept placebo, and prednisolone placebo (arm 2). The primary outcome measure was clinical inactive disease at 6 months. An exploratory phase determined the rate of clinical remission on medication (6 months of continuous clinical inactive disease) at 12 months. RESULTS: By 6 months, clinical inactive disease had been achieved in 17 (40%) of 42 patients in arm 1 and 10 (23%) of 43 patients in arm 2 (χ(2) = 2.91, P = 0.088). After 12 months, clinical remission on medication was achieved in 9 patients in arm 1 and 3patients in arm 2 (P = 0.053). There were no significant interarm differences in adverse events. CONCLUSION: Although this study did not meet its primary end point, early aggressive therapy in this cohort of children with recent-onset polyarticular JIA resulted in clinical inactive disease by 6 months and clinical remission on medication within 12 months of treatment in substantial proportions of patients in both arms.
Authors: Clara Malattia; Maria Beatrice Damasio; Angela Pistorio; Maka Ioseliani; Iris Vilca; Maura Valle; Nicolino Ruperto; Stefania Viola; Antonella Buoncompagni; Gian Michele Magnano; Angelo Ravelli; Paolo Tomà; Alberto Martini Journal: Ann Rheum Dis Date: 2010-11-24 Impact factor: 19.103
Authors: Pirjo Tynjälä; Paula Vähäsalo; Maarit Tarkiainen; Liisa Kröger; Kristiina Aalto; Merja Malin; Anne Putto-Laurila; Visa Honkanen; Pekka Lahdenne Journal: Ann Rheum Dis Date: 2011-05-28 Impact factor: 19.103
Authors: Carol A Wallace; Edward H Giannini; Bin Huang; Lukasz Itert; Nicolino Ruperto Journal: Arthritis Care Res (Hoboken) Date: 2011-07 Impact factor: 4.794
Authors: D J Lovell; E H Giannini; A Reiff; G D Cawkwell; E D Silverman; J J Nocton; L D Stein; A Gedalia; N T Ilowite; C A Wallace; J Whitmore; B K Finck Journal: N Engl J Med Date: 2000-03-16 Impact factor: 91.245
Authors: Timothy Beukelman; Nivedita M Patkar; Kenneth G Saag; Sue Tolleson-Rinehart; Randy Q Cron; Esi Morgan DeWitt; Norman T Ilowite; Yukiko Kimura; Ronald M Laxer; Daniel J Lovell; Alberto Martini; C Egla Rabinovich; Nicolino Ruperto Journal: Arthritis Care Res (Hoboken) Date: 2011-04 Impact factor: 4.794
Authors: H M Albers; D M C Brinkman; S S M Kamphuis; L W A van Suijlekom-Smit; M A J van Rossum; E P A H Hoppenreijs; H J Girschick; C Wouters; R K Saurenmann; J J Houwing-Duistermaat; T W J Huizinga; M W Schilham; R ten Cate Journal: Arthritis Care Res (Hoboken) Date: 2010-02 Impact factor: 4.794
Authors: Daniel J Lovell; Nicolino Ruperto; Steven Goodman; Andreas Reiff; Lawrence Jung; Katerina Jarosova; Dana Nemcova; Richard Mouy; Christy Sandborg; John Bohnsack; Dirk Elewaut; Ivan Foeldvari; Valeria Gerloni; Jozef Rovensky; Kirsten Minden; Richard K Vehe; L Wagner Weiner; Gerd Horneff; Hans-Iko Huppertz; Nancy Y Olson; John R Medich; Roberto Carcereri-De-Prati; Melissa J McIlraith; Edward H Giannini; Alberto Martini Journal: N Engl J Med Date: 2008-08-21 Impact factor: 91.245
Authors: Jessica Widdifield; Sasha Bernatsky; J Carter Thorne; Claire Bombardier; R Liisa Jaakkimainen; Laura Wing; J Michael Paterson; Noah Ivers; Debra Butt; Anne Lyddiatt; Catherine Hofstetter; Vandana Ahluwalia; Karen Tu Journal: CMAJ Open Date: 2016-05-11
Authors: Roberto Spreafico; Maura Rossetti; John W Whitaker; Wei Wang; Daniel J Lovell; Salvatore Albani Journal: Proc Natl Acad Sci U S A Date: 2016-11-14 Impact factor: 11.205
Authors: Courtney McCracken; Steven Yeh; Kirsten Jenkins; Curtis Travers; Daneka Stryker; Steven Tommasello; Kelly A Rouster-Stevens; Scott R Lambert; Sampath Prahalad; Carolyn Drews-Botsch; Sheila T Angeles-Han Journal: Eye (Lond) Date: 2018-11-28 Impact factor: 3.775